Timothy DeVere Cook - 22 Dec 2021 Form 3 Insider Report for Athenex, Inc.

Role: Chief Business and Commercial Officer, Proprietary Drugs Exhibit List: Exhibit 24.1 - Power of Attorney
Signature: /s/Steven Adams, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 22 Dec 2021
Net transactions value: $0
Form type: 3
Filing time: 10 Jan 2022, 15:31:42 UTC
Next filing: 29 Mar 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ATNXQ	Stock Option (Right to Buy)							22 Dec 2021	Common Stock	70,000	$17.29	Direct	F1
holding	ATNXQ	Stock Option (Right to Buy)							22 Dec 2021	Common Stock	30,000	$10.26	Direct	F2
holding	ATNXQ	Stock Option (Right to Buy)							22 Dec 2021	Common Stock	9,000	$3.56	Direct	F3
holding	ATNXQ	Restricted Stock Units							22 Dec 2021	Common Stock	9,000		Direct	F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option vests in four equal annual installments beginning on August 17, 2019.
F2	This option vests in four equal annual installments beginning on August 27, 2021.
F3	This option vests in four equal annual installments beginning on September 16, 2022.
F4	The restricted stock units vest in four equal annual installments beginning on September 16, 2022.
F5	Each restricted stock unit represents a contingent right to receive one share of stock.

Remarks:

Chief Business and Commercial Officer, Proprietary Drugs Exhibit List: Exhibit 24.1 - Power of Attorney